Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA clearance pending for Base Ten's Prenval 1

This article was originally published in Clinica

Executive Summary

Base Ten Systems (US) says it has been informally advised that the FDA will clear its Prenval 1 foetal abnormality software program as a Class 1 Tier 3 medical device under the 510(k) process. The Trenton (NJ)-based company expects to meet FDA officials by mid-July to complete the labelling details prior to formal clearance, allowing it to introduce the program by mid-September. The software was considered by the FDA's advisory panel earlier this year (see Clinica No 649, p 7).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT092018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel